S1335 Association of Faecal Calprotectin With Symptomatic, Endoscopic, and Clinical Remission in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Notice bibliographique
Résumé
Introduction: Mirikizumab (miri), a p19-directed IL-23 antibody, has been shown to be effective in patients with moderately-to-severely active ulcerative colitis (UC) in Phase 3 trials (LUCENT-1 NCT03518086; LUCENT-2 NCT03524092). The relationship between symptomatic, endoscopic, and clinical remission and levels of the inflammatory biomarker faecal calprotectin (fCAL) was studied for miri-treated patients enrolled in the trials. Methods: This post hoc analysis evaluated patients treated with intravenous (IV) miri 300mg every 4 weeks (every 4 weeks) until week (W)12 in induction (n=868) followed by subcutaneous miri (n=365) every 4 weeks up to W52 (miri induction responders at W12 who were rerandomized for the maintenance period) or placebo. The improvement in fCAL at W12 and W52 between miri and placebo were compared using Cochran Mantel Haenszel, adjusting for randomization stratification factors. Missing data were imputed as nonresponse. The relationship between achieving symptomatic, endoscopic, or clinical remission (defined in Table) and fCAL levels at W4, W12 and W52 was assessed using receiver operating characteristic (ROC) approaches. Predictability was measured by area under the ROC curve (AUC), and AUC≤0.5 indicates no predictability. Optimal fCAL threshold was obtained based on Youden Index. Results: Greater proportions of miri-treated patients compared to placebo achieved fCAL≤250 ug/g at W4, W12, and W52. A total of 19.0% vs 12.5%, 34.3% vs 20.1%, 50.7% vs 19.3% patients achieved fCAL≤250 ug/g at W4, W12, and W52 miri vs placebo, respectively. Greater proportions of patients achieving symptomatic, endoscopic, and clinical remission reached the predefined threshold of fCAL≤250 ug/g or the optimum fCAL threshold obtained from the ROC (see Table footnote) in this study compared with those not achieving the endpoints (Table 1). W4 fCAL levels had 70.5% predictability for W12 endoscopic remission and 64.9% for clinical remission, but lower predictability for symptomatic remission (59.1%). W12 fCAL levels had 83.0% predictability for W12 endoscopic remission, 78.5% for clinical remission, and 67.4% for symptomatic remission. W52 fCAL levels had higher predictability for W52 endoscopic (76.6%) and clinical remission (72.7%) than for symptomatic remission (62.3%). Conclusion: These results support the use of fCAL as an early predictor of clinical outcomes and as a non-invasive biomarker for predicting clinical outcomes. Table 1. - Faecal Calprotectin Normalization at Week 12 in LUCENT-1 and Week 52 in LUCENT-2 Per Achievement of Efficacy Outcomes Symptomatic Remission Endoscopic Remission Clinical Remission Week 4 Achieving (N=360) Not Achieving (N=406) Achieving (N=290) Not Achieving (N=478) Achieving (N=193) Not Achieving (N=571) fCAL ≤ 250 ug/g 109 (30.3) 79 (19.5)╪ 122 (42.1) 65 (13.6) ╪ 77 (39.9) 110 (19.3)╪ Optimum fCAL threshold 193 (53.6) 159(39.2)╪ 158 (54.5) 106 (22.2)╪ 103 (53.4) 168 (29.4)╪ Week 12 Achieving (N=364) Not Achieving (N=398) Achieving (N=293) Not Achieving (N=472) Achieving (N=199) Not Achieving (N=562) fCAL ≤ 250 ug/g 200 (55.0) 116 (29.2)╪ 216 (73.7) 100 (21.2)╪ 151 (75.9) 164 (29.2)╪ Optimum fCAL threshold 237 (65.1) 149 (37.4)╪ 216 (73.7) 93 (19.7)╪ 151 (75.9) 157 (27.9)╪ Week 52 Achieving (N=230) Not Achieving (N=44) Achieving (N=188) Not Achieving (N=93) Achieving (N=166) Not Achieving (N=107) fCAL ≤ 250 ug/g 161 (70.0) 22 (50.0)* 151 (80.3) 38 (40.9)╪ 133 (80.1) 49 (45.8)╪ Optimum fCAL threshold 161 (70.0) 21 (47.7)* 134 (71.3) 24 (25.8)╪ 129 (77.7) 42 (39.3)╪ Abbreviations: ES=Endoscopic Subscore; fCAL=Fecal Calprotectin; RB = Rectal Bleeding; SF=Stool Frequency.Note: Data shown as n(%) unless otherwise noted. *P < 0.05 and ╪P < 0.001; P-value is from Fisher's exact test.Symptomatic remission is defined as SF = 0 or SF = 1 with a ≥ 1-point decrease from baseline, and RB = 0. Endoscopic Remission is defined as ES = 0 or 1 (excluding friability). Clinical remission is defined as SF = 0 or SF = 1 with a ≥ 1-point decrease from baseline, RB = 0, and ES = 0 or 1 (excluding friability). Optimal fCAL threshold for symptomatic remission/endoscopic remission/ and clinical remission is at ≤585/≤390/≤415 ug/g at Week 4, ≤365/≤230/≤230 ug/g at Week 12, and ≤230/≤150/≤205 ug/g at Week 52, respectively.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,001 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,002 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».